Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Immunotherapy, 2001-09, Vol.50 (7), p.337-344
Hauptverfasser: KIKUCHI, Tetsuro, AKASAKI, Yasuharu, IRIE, Masaki, HOMMA, Sadamu, ABE, Toshiaki, OHNO, Tsuneya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 344
container_issue 7
container_start_page 337
container_title Cancer Immunology, Immunotherapy
container_volume 50
creator KIKUCHI, Tetsuro
AKASAKI, Yasuharu
IRIE, Masaki
HOMMA, Sadamu
ABE, Toshiaki
OHNO, Tsuneya
description Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.
doi_str_mv 10.1007/s002620100205
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11032998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72225496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-f77ec4eb49b2ddc68adf3aa4719f8385d7850fba999eba0d694513d563d1aedd3</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxS0Eokvh2GuVQ4W4BDy2E9unqqr4qFQJCcHZmvij6yrrbO2kVf97vHSB9gIXe-z5zdM8PUKOgL4HSuWHQinrGa01o90zsgLBWUtVB8_JinJBW0mpOCCvSrmuBaNavyQHAL3sueYrsv3myzLOpZlCg812jcU3F40dY4oWx2bOsZ61d4vWxoRznNLueTXGaVP5-uFTnb6L87oJS6ntX1LOJ5fjHG2Dyf2mrR_H8pq8CDgW_2Z_H5Ifnz5-P__SXn79fHF-dtlawdXcBim9FX4QemDO2V6hCxxRSNBBcdU5qToaBtRa-wGp67XogLuu5w7QO8cPyemD7nYZNt7ZumbG0Wxz3GC-NxNG87ST4tpcTbcGgHKmtaoKb_cKebpZfJnNJpadB0x-WoqRjLFO6L6C7_4JgpJSAVcA_9UExatFLivYPoA2T6VkH_5sDtTsgjdPgq_88WO7f-l90hU42QNYarIhY7KxPOI4Y6D5T_-ItwA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18347137</pqid></control><display><type>article</type><title>Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>PubMed Central</source><creator>KIKUCHI, Tetsuro ; AKASAKI, Yasuharu ; IRIE, Masaki ; HOMMA, Sadamu ; ABE, Toshiaki ; OHNO, Tsuneya</creator><creatorcontrib>KIKUCHI, Tetsuro ; AKASAKI, Yasuharu ; IRIE, Masaki ; HOMMA, Sadamu ; ABE, Toshiaki ; OHNO, Tsuneya</creatorcontrib><description>Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s002620100205</identifier><identifier>PMID: 11676393</identifier><identifier>CODEN: CIIMDN</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; Cell Fusion ; Child, Preschool ; Dendritic Cells - immunology ; Female ; Glioma - immunology ; Glioma - therapy ; Humans ; Immunotherapy ; Interferon-gamma - biosynthesis ; Male ; Medical sciences ; Middle Aged ; Original ; Pharmacology. Drug treatments ; T-Lymphocytes - immunology ; Vaccination</subject><ispartof>Cancer Immunology, Immunotherapy, 2001-09, Vol.50 (7), p.337-344</ispartof><rights>2001 INIST-CNRS</rights><rights>Springer-Verlag 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-f77ec4eb49b2ddc68adf3aa4719f8385d7850fba999eba0d694513d563d1aedd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032998/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032998/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1132219$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11676393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KIKUCHI, Tetsuro</creatorcontrib><creatorcontrib>AKASAKI, Yasuharu</creatorcontrib><creatorcontrib>IRIE, Masaki</creatorcontrib><creatorcontrib>HOMMA, Sadamu</creatorcontrib><creatorcontrib>ABE, Toshiaki</creatorcontrib><creatorcontrib>OHNO, Tsuneya</creatorcontrib><title>Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Fusion</subject><subject>Child, Preschool</subject><subject>Dendritic Cells - immunology</subject><subject>Female</subject><subject>Glioma - immunology</subject><subject>Glioma - therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Pharmacology. Drug treatments</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccination</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAQxS0Eokvh2GuVQ4W4BDy2E9unqqr4qFQJCcHZmvij6yrrbO2kVf97vHSB9gIXe-z5zdM8PUKOgL4HSuWHQinrGa01o90zsgLBWUtVB8_JinJBW0mpOCCvSrmuBaNavyQHAL3sueYrsv3myzLOpZlCg812jcU3F40dY4oWx2bOsZ61d4vWxoRznNLueTXGaVP5-uFTnb6L87oJS6ntX1LOJ5fjHG2Dyf2mrR_H8pq8CDgW_2Z_H5Ifnz5-P__SXn79fHF-dtlawdXcBim9FX4QemDO2V6hCxxRSNBBcdU5qToaBtRa-wGp67XogLuu5w7QO8cPyemD7nYZNt7ZumbG0Wxz3GC-NxNG87ST4tpcTbcGgHKmtaoKb_cKebpZfJnNJpadB0x-WoqRjLFO6L6C7_4JgpJSAVcA_9UExatFLivYPoA2T6VkH_5sDtTsgjdPgq_88WO7f-l90hU42QNYarIhY7KxPOI4Y6D5T_-ItwA</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>KIKUCHI, Tetsuro</creator><creator>AKASAKI, Yasuharu</creator><creator>IRIE, Masaki</creator><creator>HOMMA, Sadamu</creator><creator>ABE, Toshiaki</creator><creator>OHNO, Tsuneya</creator><general>Springer</general><general>Springer-Verlag</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20010901</creationdate><title>Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells</title><author>KIKUCHI, Tetsuro ; AKASAKI, Yasuharu ; IRIE, Masaki ; HOMMA, Sadamu ; ABE, Toshiaki ; OHNO, Tsuneya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-f77ec4eb49b2ddc68adf3aa4719f8385d7850fba999eba0d694513d563d1aedd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Fusion</topic><topic>Child, Preschool</topic><topic>Dendritic Cells - immunology</topic><topic>Female</topic><topic>Glioma - immunology</topic><topic>Glioma - therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Pharmacology. Drug treatments</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KIKUCHI, Tetsuro</creatorcontrib><creatorcontrib>AKASAKI, Yasuharu</creatorcontrib><creatorcontrib>IRIE, Masaki</creatorcontrib><creatorcontrib>HOMMA, Sadamu</creatorcontrib><creatorcontrib>ABE, Toshiaki</creatorcontrib><creatorcontrib>OHNO, Tsuneya</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KIKUCHI, Tetsuro</au><au>AKASAKI, Yasuharu</au><au>IRIE, Masaki</au><au>HOMMA, Sadamu</au><au>ABE, Toshiaki</au><au>OHNO, Tsuneya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>50</volume><issue>7</issue><spage>337</spage><epage>344</epage><pages>337-344</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><coden>CIIMDN</coden><abstract>Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>11676393</pmid><doi>10.1007/s002620100205</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology, Immunotherapy, 2001-09, Vol.50 (7), p.337-344
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11032998
source MEDLINE; SpringerNature Journals; PubMed Central
subjects Adult
Antineoplastic agents
Biological and medical sciences
Cell Fusion
Child, Preschool
Dendritic Cells - immunology
Female
Glioma - immunology
Glioma - therapy
Humans
Immunotherapy
Interferon-gamma - biosynthesis
Male
Medical sciences
Middle Aged
Original
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Vaccination
title Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T23%3A35%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20a%20phase%20I%20clinical%20trial%20of%20vaccination%20of%20glioma%20patients%20with%20fusions%20of%20dendritic%20and%20glioma%20cells&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=KIKUCHI,%20Tetsuro&rft.date=2001-09-01&rft.volume=50&rft.issue=7&rft.spage=337&rft.epage=344&rft.pages=337-344&rft.issn=0340-7004&rft.eissn=1432-0851&rft.coden=CIIMDN&rft_id=info:doi/10.1007/s002620100205&rft_dat=%3Cproquest_pubme%3E72225496%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18347137&rft_id=info:pmid/11676393&rfr_iscdi=true